<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01993212</url>
  </required_header>
  <id_info>
    <org_study_id>ZA-304</org_study_id>
    <nct_id>NCT01993212</nct_id>
  </id_info>
  <brief_title>A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men&#xD;
      with Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm&#xD;
      Concentration Following Treatment with the 12.5 mg or 25 mg Androxal or AndroGel 1.62%.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the proportion of subjects meeting the composite endpoint for normal morning testosterone and semen concentration.</measure>
    <time_frame>16 weeks of treatment</time_frame>
    <description>Comparison of the proportion of subjects whose morning testosterone levels are within the normal range [300-1,040 ng/dL] and whose sperm concentration is 15 million/mL or greater following 16 weeks of treatment with Androxal, placebo or AndroGel 1.62%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with mean sperm concentration less than 15 million/mL after 16 weeks of treatment comparing Androxal to placebo in a non-inferiority assessment</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Secondary Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Androxal Placebo and Gel Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AndroGel Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AndroGel 1.62% and Placebo Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Androxal Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Androxal 12.5 mg or 25mg and Placebo Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androxal 12.5 mg or 25 mg</intervention_name>
    <arm_group_label>Androxal Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AndroGel 1.62%</intervention_name>
    <arm_group_label>AndroGel Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Capsules</intervention_name>
    <arm_group_label>AndroGel Treatment</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Gel</intervention_name>
    <arm_group_label>Androxal Treatment</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overweight (BMI 25 to 42 kg/m2 inclusive) males age 18 to 60 inclusive&#xD;
&#xD;
          -  Previously or concurrently diagnosed as having secondary hypogonadism characterized as&#xD;
             having at least 2 consecutive morning testosterone assessments &lt; 300ng/dL, one of&#xD;
             which must be confirmed at Baseline.&#xD;
&#xD;
          -  LH &lt; 9.4 mIU/mL (at Visit 1 only)&#xD;
&#xD;
          -  Sperm concentration ≥ 15 million per milliliter (assessed at V2 and Baseline). V2 and&#xD;
             Baseline measurements must be at least 48 hours apart.&#xD;
&#xD;
          -  Ability to complete the study in compliance with the protocol&#xD;
&#xD;
          -  Ability to understand and provide written informed consent&#xD;
&#xD;
          -  Agreement to provide a total of at least 4 semen samples in a sponsor-approved clinic&#xD;
             on 4 separate occasions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior use of testosterone treatments (injectable, pelleted, transdermal or&#xD;
             sublingual) within the last 6 months&#xD;
&#xD;
          -  Use of spironolactone, cimetidine, Clomid, 5α-reductase inhibitors, hCG, androgen,&#xD;
             estrogen, anabolic steroid, DHEA, or herbal hormone products during the study&#xD;
&#xD;
          -  Use of Clomid in the past year&#xD;
&#xD;
          -  Any clinically significant laboratory abnormality that does not have prior written&#xD;
             sponsor approval. If the sponsor approves subject enrollment, this will not be&#xD;
             considered to be a protocol deviation.&#xD;
&#xD;
          -  Uncontrolled hypertension or diabetes mellitus based on the Investigator's assessment&#xD;
             at baseline. Subjects treated for Type II diabetes will be allowed into the study, if&#xD;
             considered clinically stable by the investigator. Newly diagnosed diabetics need to be&#xD;
             treated for at least 48 hours before being enrolled in the study.&#xD;
&#xD;
          -  A hematocrit &gt;54&#xD;
&#xD;
          -  Use of an investigational drug or product, or participation in a drug or medical&#xD;
             device research study within 30 days prior to receiving study medication.&#xD;
&#xD;
          -  Known hypersensitivity to Clomid&#xD;
&#xD;
          -  Symptomatic cataracts (nuclear sclerosis cataract or cortical cataract grade &gt; 2 based&#xD;
             on 0-4 scale or any evidence of posterior subcapsular cataract)&#xD;
&#xD;
          -  Abnormal fundoscopy exam such as central retinal vein occlusion&#xD;
&#xD;
          -  Any condition which in the opinion of the investigator would interfere with the&#xD;
             participant's ability to provide informed consent, comply with study instructions,&#xD;
             possibly confound interpretation of study results, or endanger the participant if he&#xD;
             took part in the study&#xD;
&#xD;
          -  Have received a diagnosis of irreversible infertility or compromised fertility&#xD;
             (cryptorchism, Kallman Syndrome, primary hypogonadism, vasectomy, or tumors of the&#xD;
             pituitary), or history of evaluation or treatment for low fertility&#xD;
&#xD;
          -  Current or history of breast cancer&#xD;
&#xD;
          -  Current or history of prostate cancer or a suspicion of prostate disease unless ruled&#xD;
             out by prostate biopsy, or a PSA&gt;3.6&#xD;
&#xD;
          -  Presence or history of known hyperprolactinemia with or without a tumor (prolactin &gt;&#xD;
             20 ng/mL).&#xD;
&#xD;
          -  Chronic use of medications such as glucocorticoids (chronic use of inhaled or topical&#xD;
             glucocorticoids is acceptable)&#xD;
&#xD;
          -  History of drug abuse or chronic narcotic use including methadone&#xD;
&#xD;
          -  A recent history of alcoholism or illegal substance or steroid abuse (&lt;2 years) or&#xD;
             presence of moderate alcohol use (&gt;21 drinks per week)&#xD;
&#xD;
          -  Subjects with known history of HIV and/or Hepatitis C&#xD;
&#xD;
          -  Subjects with end stage renal disease&#xD;
&#xD;
          -  History of liver disease (including malignancy) or a confirmed AST or ALT &gt;3 times the&#xD;
             upper limit of normal&#xD;
&#xD;
          -  History of clinically relevant myocardial infarction (within the previous year),&#xD;
             unstable angina, symptomatic heart failure, ventricular dysrhythmia or know history of&#xD;
             QTc interval prolongation&#xD;
&#xD;
          -  History of clinically relevant cerebrovascular disease&#xD;
&#xD;
          -  History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary&#xD;
             embolism)&#xD;
&#xD;
          -  History of erythrocytosis or polycythemia&#xD;
&#xD;
          -  Subjects unable to provide a semen sample in a sponsor-approved clinic&#xD;
&#xD;
          -  Enrollment in a previous Androxal study&#xD;
&#xD;
          -  Subjects who have Type I Diabetes&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>November 13, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low Testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

